The influence of physiological and surgical menopause on coronary heart disease risk markers

Menopause

Volumn 16, Issue 1, 2009, Pages 37-49

  Verhoeven, Marieke O ^a   Van Der Mooren, Marius J ^a   Teerlink, Tom ^a   Verheijen, René H M ^b   Scheffer, Peter G ^a   Kenemans, Peter ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arginine; Asymmetric dimethylarginine; Cardiovascular risk factors; Preventive bilateral salpingo ovariectomy; Symmetric dimethylarginine

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; FOLLITROPIN; HOMOCYSTEINE; INHIBIN A; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; SEX HORMONE; UBIDECARENONE; ARGININE; BIOLOGICAL MARKER; DIMETHYLARGININE; DRUG DERIVATIVE; INHIBIN; INHIBIN B; LIPID; UBIQUINONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; PROPHYLAXIS; SALPINGOOOPHORECTOMY; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; LONGITUDINAL STUDY; MIDDLE AGED; OVARIECTOMY; PHYSIOLOGY; RISK FACTOR;

ARGININE; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY DISEASE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HOMOCYSTEINE; HUMANS; INHIBINS; LEPTIN; LIPIDS; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; RISK FACTORS; UBIQUINONE;

EID: 62749148694     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817c42d6     Document Type: Article

References (53)

1. Van der Mooren MJ, Kenemans P. Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life. Drugs 2004;64:821-836.
2. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780.
3. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733-738.
4. Van der Voort DJM, van de Weijer PHM, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003;14:525-530.
5. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
6. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57-61.
7. Van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-718.
8. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. A review. Ann N Y Acad Sci 1990;592:193-203.
9. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641.
10. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-733.
11. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
12. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954.
13. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-2128.
14. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-e59.
15. Alleva R, Tomasetti M, Battino M, Curatola G, Littarru GP, Folkers K. The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions. Proc Natl Acad Sci U S A 1995;92:9388-9391.
16. De Jong S, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 2006;353:287-289.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Hansen G, Christensen P, Tuchsen E, Lund T. Sensitive and selective analysis of coenzyme Q10 in human serum by negative APCI LC-MS. Analyst 2004;129:45-50.
19. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
20. Antill Y, Reynolds J, Young MA, et al. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 2006;42:621-628.
21. Leunen K, Legius E, Moerman P, Amant F, Neven P, Vergote I. Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer 2006;16:183-188.
22. Zoccali C, Bode-Böger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
23. Nijveldt RJ, Teerlink T, van der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003;22:23-30.
24. Peng WJ, Jiang JL, Jia SJ, et al. Asymmetric dimethylarginine is not involved in ovariectomy-induced osteopenia in rats. Comp Med 2005;55:30-33.
25. Li XP, Zhou Y, Zhao SP, Gao M, Zhou QC, Li YS. Effect of endogenous estrogen on endothelial function in women with coronary heart disease and its mechanism. Clin Chim Acta 2004;339:183-188.
26. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH. Determination of a reference value for NG, NG-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622-626.
27. Teerlink T, Neele SJM, de Jong S, Netelenbos JC, Stehouwer CDA. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci 2003;105:67-71.
28. Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CDA, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003;88:4221-4226.
29. Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med 2006;259:199-208.
30. Fukami K, Koike K, Hirota K, Yoshikawa H, Miyake A. Perimenopausal changes in serum lipids and lipoproteins: a 7-year longitudinal study. Maturitas 1995;22:193-197.
31. Carr MC, Kim KH, Zambon A, et al. Changes in LDL density across the menopausal transition. J Investig Med 2000;48:245-250.
32. Hall G, Collins A, Csemiczky G, Landgren BM. Lipoproteins and BMI: a comparison between women during transition to menopause and regularly menstruating healthy women. Maturitas 2002;41:177-185.
33. Azizi F, Ainy E. Coronary heart disease risk factors and menopause: a study in 1980 Tehranian women, the Tehran Lipid and Glucose Study. Climacteric 2003;6:330-336.
34. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003;88:4823-4831.
35. Guthrie JR, Dudley EC, Dennerstein L, Hopper JL. Changes in physical activity and health outcomes in a population-based cohort of mid-life Australian-born women. Aust N Z J Public Health 1997;21:682-687.
36. Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol 2000;151:584-593.
37. Palan PR, Connell K, Ramirez E, et al. Effects of menopause and hormone replacement therapy on serum levels of coenzyme Q10 and other lipid-soluble antioxidants. Biofactors 2005;25:61-66.
38. Hadji P, Bock K, Gotschalk M, et al. The influence of serum leptin concentration on bone mass assessed by quantitative ultrasonometry in pre and postmenopausal women. Maturitas 2003;44:141-148.
39. Jen KL, Buison A, Darga L, Nelson D. The relationship between blood leptin level and bone density is specific to ethnicity and menopausal status. J Lab Clin Med 2005;146:18-24.
40. Douchi T, Iwamoto I, Yoshimitsu N, Kosha S, Nagata Y. Leptin production in pre- and postmenopausal women. Maturitas 2002;42:219-223.
41. Pansini F, Bonaccorsi G, Calisesi M, et al. Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturitas 1993;17:181-190.
42. Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-805.
43. Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163-168.
44. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-722.
45. Van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999;81:925-928.
46. Post MS, van der Mooren MJ, Stehouwer CDA, et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb Haemost 2002;88:605-610.
47. Guthrie JR, Clark MS, Dennerstein L, Burger HG. Serum C-reactive protein and plasma homocysteine levels are associated with hormone therapy use and other factors: a population-based study of middle-aged Australian-born women. Climacteric 2005;8:263-270.
48. Sowers MR, Matthews KA, Jannausch M, et al. Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab 2005;90:5942-5948.
49. Stefánska A, Sypniewskay G, Senterkiewicz L. Inflammatory markers and cardiovascular risk in healthy polish women across the menopausal transition. Clin Chem 2005;51:1893-1895.
50. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-4030.
51. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-2838.
52. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 1985;61:564-570.
53. Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118:793-798.